1. COVID-19, Oxidative Stress, and Neuroinflammation in the Depression Route
- Author
-
Maiqueli Eduarda Dama Mingoti, Amanda Gollo Bertollo, Júlia Leão Batista Simões, Gabriel Rossi Francisco, Margarete Dulce Bagatini, and Zuleide Maria Ignácio
- Subjects
Inflammation ,Depressive Disorder, Major ,Oxidative Stress ,Cellular and Molecular Neuroscience ,Depression ,Neuroinflammatory Diseases ,COVID-19 ,Humans ,Indoleamine-Pyrrole 2,3,-Dioxygenase ,General Medicine ,Kynurenine - Abstract
COVID-19 is associated with oxidative stress, peripheral hyper inflammation, and neuroinflammation, especially in individuals with a more severe form of the disease. Some studies provide evidence on the onset or exacerbation of major depressive disorder (MDD), among other psychiatric disorders due to COVID-19. Oxidative stress and neuroinflammation are associated conditions, especially in the more severe form of MDD and in refractoriness to available therapeutic strategies. Inflammatory cytokines in the COVID-19 hyper inflammation process can activate the hypothalamic-pituitary-adrenal (HPA) axis and the indoleamine-2,3-dioxygenase (IDO) enzyme. IDO activation can reduce tryptophan and increase toxic metabolites of the kynurenine pathway, which increases glial activation, neuroinflammation, toxicity, and neuronal death. This review surveyed a number of studies and analyzed the mechanisms of oxidative stress, inflammation, and neuroinflammation involved in COVID-19 and depression. Finally, the importance of more protocols that can help elucidate the interaction between these mechanisms underlying COVID-19 and MDD and the possible therapeutic strategies involved in the interaction of these mechanisms are highlighted.
- Published
- 2022
- Full Text
- View/download PDF